ValGenesis, Inc., the global leader in digital validation lifecycle management, announced a strategic partnership with CAI, a professional services firm specializing in accelerating operational readiness in mission-critical environments, to expand the use of artificial intelligence (AI) in life sciences validation.
Through the partnership, CAI will deliver implementation services for ValGenesis’ AI-enabled platform, helping life sciences companies modernize their validation processes, reduce manual effort, and improve compliance outcomes. This collaboration aims to provide more efficient tech transfer across sites and programs, turning validation from a bottleneck into a strategic advantage. ValGenesis’ Smart GxP™ Platform transforms how life sciences companies manage data, processes, and compliance. It bridges the gap between R&D, validation, and manufacturing, unifying validation and process development in a single, scalable, AI-enabled platform. By digitally connecting all stages of the product lifecycle, the platform supports a closed-loop feedback cycle from process development to commercial manufacturing.
Also Read: Quiver Bioscience Gets Funding to Boost CNS Drug Platform
“At CAI, we see digital validation not just as a tool for compliance—but as a catalyst for innovation and speed,” said Sheena Dempsey, CEO of CAI. “This partnership with ValGenesis allows us to help our life sciences clients turn regulatory requirements into strategic advantages. By integrating AI-enabled platforms with our elite field expertise, we’re enabling companies to get therapies to patients faster, smarter, and with greater confidence.”
“ValGenesis is enabling faster market entry for vital therapies by transforming how life sciences companies approach validation,” said Dr. Siva Samy, CEO and Chief Product Strategist at ValGenesis. “By partnering with CAI, we’re ensuring that customers benefit not just from advanced technology, but from the expert services needed to implement and scale it successfully.”
Source: Businesswire
